A multi-center, phase 2, randomized, controlled study of the effect of lyophilized plasma in patients with liver disease.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Licensed plasma that has been lyophilized.
Plasma that has been authorized for transfusion.
Assess and compare adverse events
The primary safety objective is to assess the incidence of adverse events of lyophilized plasma compared to control.
Time frame: Duration of Study (Less than or equal to 7 days)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.